Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 08, 2025 08:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

Objective response rate (ORR) of 75.0% including three very good partial responses (VGPR) in heavily pre-treated Waldenström macroglobulinemia patients With a median follow up of 8.1 months, median...
December 06, 2025 09:30 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition

Objective response rate (ORR) of 83% including two complete responses in CLL patients in Phase 1a study with median progression free survival (PFS) of 22.1 months across all doses tested Emerging...
December 01, 2025 07:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

SAN FRANCISCO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
November 25, 2025 07:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

SAN FRANCISCO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
November 10, 2025 07:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors

SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
November 07, 2025 09:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling

New translational data supports potential of NX-1607 as a novel next generation checkpoint inhibitor therapy
November 03, 2025 09:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting

Nurix presents new data from bexobrutideg Ph 1a/1b clinical trial in patients with r/r CLL and updates in patients with WM at #ASH25
October 30, 2025 07:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics to Participate in Upcoming Investor Conferences

SAN FRANCISCO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
October 27, 2025 07:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock

SAN FRANCISCO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
October 22, 2025 07:20 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock

SAN FRANCISCO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...